John Hussman's BCRX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 252,000 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $1.97 M, representing 0.48% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, John Hussman has maintained this position in BCRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 42,000 shares. Largest reduction occurred in Q2 2025, reducing 105,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +42,000 | Add 20.00% | 252,000 | $7.80 |
| Q2 2025 | -105,000 | Reduce 33.33% | 210,000 | $8.96 |
| Q1 2025 | +315,000 | New Buy | 315,000 | $7.50 |
John Hussman's BioCryst Pharmaceuticals Investment FAQs
John Hussman first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q1 2025, acquiring 315,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held BioCryst Pharmaceuticals, Inc. (BCRX) for 4 quarters since Q1 2025.
John Hussman's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q1 2025, adding 315,000 shares worth $2.36 M.
According to the latest 13F filing for Q4 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 252,000 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $1.97 M.
As of the Q4 2025 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.48% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 315,000 shares, as reported at the end of Q1 2025.